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Abstract
Although the molecular function of S receptors has
not been fully defined and the natural ligand(s) is still
not known, there is increasing evidence that these
receptors and their ligands might play a significant
role in cancer biology. 4-(N-benzylpiperidin-4-yl)-4-
iodobenzamide (4-IBP), a selective S1 agonist, has been
used to investigate whether this compound is able to
modify: 1) in vitro the migration and proliferation of
human cancer cells; 2) in vitro the sensitivity of human
glioblastoma cells to cytotoxic drugs; and 3) in vivo
in orthotopic glioblastoma and non–small cell lung
carcinoma (NSCLC) models the survival of mice co-
administered cytotoxic agents. 4-IBP has revealed
weak antiproliferative effects on human U373-MG glio-
blastoma and C32 melanoma cells but induced marked
concentration-dependent decreases in the growth of
human A549 NSCLC and PC3 prostate cancer cells.
The compound was also significantly antimigratory in
all four cancer cell lines. This may result, at least in
U373-MG cells, from modifications to the actin cyto-
skeleton. 4-IBP modified the sensitivity of U373-MG
cells in vitro to proapoptotic lomustin and proauto-
phagic temozolomide, and markedly decreased the
expression of two proteins involved in drug resistance:
glucosylceramide synthase and Rho guanine nucleo-
tide dissociation inhibitor. In vivo, 4-IBP increased the
antitumor effects of temozolomide and irinotecan in
immunodeficient mice that were orthotopically grafted
with invasive cancer cells.
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Introduction
j Receptors have been studied mostly with respect to their
functions within the central nervous system [1–4]. Additional
functions of j receptors in connection with the motor, endocrine,
and immune systems have also been suggested [5,6]. These j
receptors, however, have also been found to be overabundant
in many tumors of neural and non-neural origin [7] and might,
therefore, play a significant role in cancer biology [4]. They were
first described as a subtype of opiate receptors [8], but they
were later distinguished from them by the development of se-
lective j ligands [9]. Indeed, radioligand-binding studies sub-
sequently indicated that there are at least three, and possibly
more, subtypes of j receptors, designated as j1, j2, and j3 [3].
Radioligand-binding data have also demonstrated that the j1
receptor is related both to a sterol isomerase, which is involved in
the cholesterol biosynthesis pathway [3,6,10], and to SR31747-
binding protein-2, with which it shares a high level of homology
but which is of unknown function [11]. The j1 receptor has been
cloned [12,13], and five transcription variants are known (Gene
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Bank Data Base: NM_005866, NM_147157, NM_147158,
NM_147159, and NM_147160).
Both j1 and j2 receptor subtypes are highly expressed in
tumor cell lines from various human cancers, including small
cell lung carcinoma and non–small cell lung carcinoma
(NSCLC), renal carcinomas, colon carcinomas, sarcomas,
brain tumors, breast cancers, melanomas, and prostate can-
cers [4]. Small molecules that bind to the j receptor (j ligands
or j-modulating drugs) havemany potential functions [10] and
are used in diagnostic tumor imaging [14]. Such compounds
are also able to modify the growth rates of human cancer cell
lines both in vitro [6,15–17] and in vivo [18,19]. These drug-
induced decreases in cell growth rate seem to occur through
rises in intracellular calcium ([Ca2+]i) and through apoptosis
[17]. It has also been suggested that these effects on cell
growth and apoptosis occur by the sphingolipid pathway [20].
Migratory (and metastatic) cancer cells are resistant to
apoptosis, as revealed in ever more publications [21]. How-
ever, decreasing the levels of migration of tumor cells can
restore a certain level of sensitivity to cytotoxic insult [22]. Al-
though several reports have emphasized a potential role for
the j receptor and/or j-modulating drugs in reducing cancer
cell proliferation and/or increasing cancer cell death, no study
has been published to date, at least to the best of our knowl-
edge, concerning their potential role either in cancer cell mi-
gration or in the modulation of the effects of proapoptotic and
proautophagic drugs. In this context, 4-(N-benzylpiperidin-4-
yl)-4-iodobenzamide (4-IBP), a selective j1 agonist [23,24]
with a high level of affinity for the j1 receptor (Ki = 1.7 nM) and
a moderate affinity for the j2 receptor (Ki = 25.2 nM) [10,25],
was used to investigate whether targeting the j1 receptor
could modify in vitro the migration rates of human cancer cells
and increase in vitro and in vivo the sensitivity of metasta-
sizing human A549 NSCLC cells and infiltrating human glio-
blastoma cells to cytotoxic insults of either proapoptotic or
proautophagic drugs. A j1 receptor agonist, rather than an
antagonist, was used because we wanted to mimic a biologic
situation in which the j1 receptor is activated, as it might be,
by yet to be identified endogenous ligands.
Materials and Methods
Cell Lines
Four human cancer cell lines—PC3 prostate (ATCC
code CRL-1435), A549 NSCLC (CLL-185), C32 melanoma
(CRL-1585), and U373-MG glioblastoma (HTB-17)—were
obtained from the American Type Culture Collection (Manas-
sas, VA) and thereafter maintained in vitro in accordance
with their recommendations.
Compounds
4-IBP was obtained from Tocris Bioscience (Bristol,
UK). Temozolomide was obtained from Schering Plough
(Brussels, Belgium), lomustin was from Medac (Hamburg,
Germany), and irinotecan (IRI) was from Sanofi-Aventis
(Paris, France).
Standard Reverse Transcription–Polymerase Chain
Reaction (RT-PCR) for the Determination of r1
Receptor Variants in Human Cancer Cells
The procedure used was identical to that described
previously [26]. As detailed in Figure 1A and its legend,
two pairs of primers were used to evidence the presence
or the absence of five j1 receptor variants in human C32
melanoma, U373-MG glioblastoma multiforme (GBM), A549
NSCLC, and PC3 prostate cancer cell lines:
 Primer P1: 5V-gccttctctcgtctgatc-3V (forward) and 5V-
cgtgtactaccgtctcc-3V (reverse)
 Primer P2: 5V-ggagacggtagtacacg-3V (forward) and 5V-
agcataggagcgaagagt-3V (reverse).
Kekuda et al. [13] originally cloned functional j1 receptor
cDNA from a human placental choriocarcinoma cell (JAR)
library using a guinea pig–specific mRNA RT-PCR product
[12]. Prasad et al. [27] then detailed the structure and
organization of the human gene coding for this j1 receptor.
The gene contains four exons interrupted by three introns. A
number of researchers then submitted various transcription
variants of this mRNA directly to the Gene Bank Data Base
(without further scientific publication). These variants are
numbered from 1 to 5 and referenced as NM_005866,
NM_147157, NM_147158, NM_147159, and NM_147160,
respectively. As 4-IBP may bind differentially to these five j1
receptor variants [10], an RT-PCR approach was used to first
investigate their expression pattern in the four designated
cancer cell lines. Based on published sequences for the
above splice variants, primer set P2 was chosen as it
recognizes all five of the described splice variants in the
common region (exon 4; Figure 1A) and so yields one single
amplification fragment (Figure 1, C and D). Conversely, the
use of primer set P1 allowed distinction to be made between
V1, V3 + V4, and V2 + V5 (Figure 1, B and D). Any further
distinction between the different variants was technically
impossible because sequence differences were too small
to enable correct primer design and visible differences in the
size of the amplified fragment to be ascertained.
Protein Expression and Activity Measurements
Western blot analysis and immunofluorescence analyses
were performed as detailed previously [26,28]. The proteins
were detected by the following primary antibodies: anti-
ORP150 (dilution 1/100; IBL, Minneapolis, MN), anti-GRP78
(dilution 1/250; Sigma-Aldrich, Bornem, Belgium), anti-p53
(dilution 1/1000; Calbiochem VWR International, Leuven,
Belgium), anti–Beclin-1 (dilution 1/250; BD Transduction Labo-
ratories, Erembodegem, Belgium), anti-Hsp70 (dilution 1/500;
Cell Signaling, Bioke´, Leiden, The Netherlands), anti–Rho
guanine nucleotide dissociation inhibitor (Rho GDI; dilution
1/500; Cell Signaling), and anti–glucosylceramide synthase
(GCS; dilution, 5 mg/ml; Exalpha Biologicals, Inc., Mahnard,
MA). The levels of both total and phospho p85-PI3K and
Akt expressions were determined using the Fast Activated
Cell–Based ELISA Kit (Active Motif, Rixensart, Belgium).
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Determination of Apoptosis and Autophagy
Apoptosis was analyzed by flow cytometry using the
terminal deoxynucleotidyl transferase deoxyuridine triphos-
phate nick-end labeline (TUNEL) technique, as well as by
the analysis of the cleavage pattern of poly(ADP-ribose)
polymerase (PARP), which was assessed by Western blot
analysis using anti-PARP antibody (1/250; BD PharMingen,
Erembodegem, Belgium), as detailed previously [26]. Auto-
phagy was analyzed by the staining of acidic vesicular organ-
elles with acridine orange (purchased from Polysciences,
Warrington, PA), as detailed elsewhere [29]. Western blot
analyses of light chain 3 (LC3), a specific marker of auto-
phagy, were also performed with a rabbit–anti-LC3 antibody
raised in our laboratory [29]. Flow cytometry analyses were
performed immediately after a staining reaction on an Epics
XL.MCL flow cytometer (Beckman Coulter, Miami, FL)
equipped with a 488-nm argon laser.
In Vitro Characterization of 4-IBP–Induced Effects on
the Growth Rates of Human Cancer Cell Populations
The influence of 4-IBP on the overall growth rates of the
four human cancer cell lines under study was determined by
colorimetric MTT assay, as previously described [28]. Each
experiment was conducted in sextuplicate. Nine 4-IBP con-
centrations ranging from 109 to 105 M (with semilog
increases in concentration) were evaluated. Cancer cells
had been incubated with 4-IBP for 3 days before overall
growth rates were determined.
In Vitro Characterization of 4-IBP Antimigratory Activity
in Human Cancer Cells
Human cell motility was characterized using computer-
assisted phase-contrast microscopy to quantitatively deter-
mine the levels of migration of individual human cancer
cells in vitro, as described previously [30]. The effect of
4-IBP on cell motility levels in C32, PC3, A549, and U373-
MG human cancer cell lines was investigated at 1, 10, and
100 nM. Figure 2C shows a typical analysis based on
individual cell trajectories, established by a cell-tracking
algorithm based on an image series acquired during a cell
migration experiment. The greatest linear distance between
a cell’s starting point and the farthest point reached in
its trajectory, the maximum relative distance from the point
of origin (MRDO), was the quantitative variable [30] used
Figure 1. Expression of the splice variants of r1 receptor mRNA (V1–V5) in four different human cancer cell lines, namely, melanoma (C32), refractory prostate
(PC3), NSCLC (A549), and glioma (U373-MG) cells, as assessed by RT-PCR analyses. (A) Schematic representation of the five different splice variants of r1
receptor mRNA, with the exact sites targeted by two different pairs of primers (P1 and P2) used to investigate the expression patterns of the splice variants. CDS =
mRNA-coding region. Primer positions are outlined by black (P1) and gray (P2) hatched boxes, respectively. (B and C) The detection of splice variants of r1
receptor mRNA by RT-PCR using primer pairs P1 and P2, respectively. (D) The detection of splice variants of r1 receptor mRNA by RT-PCR using primer pairs P2
and P1, respectively, and carried out on purified fragments isolated after PCR performed with ‘‘external primers’’ (PE1 and PE2). (B–D) First lane: 1-kb plus DNA
size ladder; Ct: nontemplate control (H2O). White arrows indicate the positions of different amplified splice variants. (?) Nonspecified amplification fragments (for
RT-PCR experimental details, see Materials and Methods section).
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to characterize compound-mediated effects on cancer
cell migration.
Characterization of the Organization of Actin Cytoskeleton
in Human U373-MG Glioblastoma Cells
Fluorescent phallacidin conjugated with Alexa Fluor 488
fluorochrome (Molecular Probes, Inc., Eugene, OR) was
selected to label fibrillar actin, whereas Alexa Fluor 594–
conjugated DNAseI (Molecular Probes, Inc.) was used to
stain globular actin. As described previously [31], U373-MG
GBM cells were cultured for various periods in the absence
(controls) or in the presence of 1 and 10 nM 4-IBP on glass
coverslips before fluorescence staining. The fluorescence
intensity of fluorochromes was quantified by a computer-
assisted fluorescent Olympus AX70 microscope (Omnilabo,
Antwerp, Belgium) equipped with a Megaview2 digital cam-
era and analySIS software (Soft Imaging System, Munster,
Germany). One hundred cells were quantified under each
experimental condition. Cell morphology was also charac-
terized with respect to four quantitative features provided by
the analySIS software and comprised cell area, sphericity,
elongation, and morphologic pattern.
Intracellular Calcium Measurements in Human U373-MG
Glioblastoma Cells
The procedure used here was identical to that described
previously [32]. The intensity of fluorescence was recorded
over the entire surface of single cells, and [Ca2+]i was then
calculated from the ratio of the intensities of fluorescence
excited at two defined wavelengths. For this purpose, a
standard intracellular calibration procedure was performed
after cell permeabilization with 5 mM ionomycin.
In Vitro Scratch Wound Assay
U373-MG glioblastoma cells were grown to confluence in
six-well dishes [21,26] before being pretreated with 10 nM
4-IBP for 1, 3, 7, or 24 hours in a serum-restricted medium
(5%). Scratch wounds were made by creating a denuded
linear area with a pipette tip [26]. The cells were washed
twice with phosphate-buffered saline before their incubation
with a cytotoxic agent (lomustin or temozolomide) at 1 and
10 mM in a serum-restricted medium for 16 additional hours
of post–4-IBP treatment. Four fields per well were photo-
graphed twice daily until wound healing was observed in
appropriate controls. A software developed in our laboratory
was used to quantify the percentage of the scratch wound
area filled by cells [21,26] over the period of the experiment.
Genomic Analyses
U373-MG GBM cells were either left untreated or treated
with 10 nM 4-IBP for 12 hours. RNA extraction and determi-
nation of the quality and integrity of extracted RNA were
assessed as detailed previously [26]. Full genome analyses
were performed at the VIB MicroArray Facility (UZ Gasthuis-
berg, Catholic University of Leuven, Leuven, Belgium) for
which purpose Affymetrix Human Genome U133 set Plus 2.0
(High Wycome, Buckinghamshire, UK) was used.
4-IBP Treatment of Orthotopic Xenografts of Human
U373-MG Glioblastoma in the Brains of
Immunodeficient Mice
The U373-MG GBM model was used to characterize the
in vivo antitumor effects of 4-IBP because: 1) these cells
were found to have only one j1 receptor variant (Figure 1); 2)
they are resistant to proapoptotic cytotoxic drugs [33], as are
GBM patients [22]; 3) they are sensitive to proautophagic
effects of temozolomide [29,33], as are GBM patients [34];
and 4) tumor debulking by surgery is of little, if any, thera-
peutic benefit in the case of immunodeficient mice bearing
orthotopic xenografts of the U373-MG GBM model in their
brains [35]. Orthotopic xenografts of human U373-MG GBM
were obtained by grafting 2million U373-MG cells into the left
Figure 2. Evaluation of the antiproliferative and antimotility activities of 4-IBP
in cancer cells. (A) Percentages of living cells assessed by the colorimetric
MTT assay in four human cancer cell lines (U373-MG, C32, A549, and PC3).
The data are shown as mean ± standard error with respect to the 4-IBP
concentrations used (see x-axis). (B) Distribution of MRDO values obtained
for C32 cells treated with increasing 4-IBP concentrations (see x-axis) and
those left untreated (Ct). The data show individual values (dotted) and cor-
responding medians (horizontal bars). (C) Typical quantification experiment
of the motility levels of individual cells by establishing the trajectory of each
cell centroid and by quantifying the MRDO variable (i.e., maximum distance
covered by a cell normalized by its observation time, expressed in m/hr).
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temporal lobes of 8-week-old female nu/nu mice (21–23 g;
Iffa Credo, Charles Rivers, Arbresle, France), as detailed
previously [31,35]. Forty-four mice grafted with glioblastoma
cells in thismanner were randomly assigned to four treatment
groups of 11 mice on day 10 posttumor graft and then on day
14 were treated as follows: Group 1 mice (the control) were
grafted subcutaneously with an osmotic minipump (Alzet;
Charles River Laboratories, L’Arbresle, France) that deliv-
ered the vehicle 4-IBP [saline with 1% dimethyl sulfoxide
(DMSO)] continuously through a catheter into the third ven-
tricle over a period of 28 days [35]. Group 2 mice received
treatment identical to that in Group 1, except that the
minipumps delivered a 4-IBP solution (in saline containing
1% DMSO) at a dose of 2 mg/kg. This dose had been
chosen based on the in vivo study published by Bermack
and Debonnel [10]. Group 3 mice received 12 intravenous
injections of temozolomide at a dose of 40 mg/kg. The 12
injections were performed thrice a week (on Mondays,
Wednesdays, and Fridays) over four consecutive weeks, with
the first injection falling on the 21st day post–tumor graft.
Group 4 animals received a combination of the treatments
described for Groups 2 and 3.
4-IBP Treatment of Orthotopic Xenografts of Human
A549 NSCLC in the Lungs of Immunodeficient Mice
The human A549 NSCLC model was investigated be-
cause A549 NSCLC cells are chemoresistant and produce
brain and liver metastases in nude mice [36]. Orthotopic
xenografts of human A549 NSCLC were obtained by grafting
2 million A549 NSCLC cells into the right lung of 8-week-old
female nu/nu mice (21–23 g; Iffa Credo, Charles Rivers), as
detailed previously [36]. Grafted mice were randomly allo-
cated to treatment groups, as detailed above. Group 1
received 12 intravenous injections of 50 ml of saline and
acted as the control group, with the first injection starting on
the seventh day posttumor graft. The injections were per-
formed thrice a week over four consecutive weeks. Under an
identical regimen, Group 2 received 12 intravenous injec-
tions of a 4-IBP solution at a dose of 2 mg/kg. Group 3
received 12 intravenous injections of an IRI solution at a
dose of 10 mg/kg. IRI was chosen given its proapoptotic
effects. 4-IBP treatment started on day 7 posttumor graft,
whereas IRI treatment started on day 14 postgraft. The IRI
treatment was chosen based on data previously obtained
[36]. Group 4 received the combined treatment described for
mice in Groups 2 and 3.
All in vivo experiments described in the current study were
performed based on authorization no. LA1230509 of the
Animal Ethics Committee of the Federal Department of
Health, Nutritional Safety, and the Environment (Belgium).
Data Analyses
Statistical comparisons were made by the Kruskal-Wallis
test (a nonparametric one-way analysis of variance). Where
this test revealed some significant differences, treatment
groups were then compared by applying the Mann-Whitney
test. Survival analyses were carried out by Kaplan-Meier
analyses. All statistical analyses were performed using Sta-
tistica (Statsoft, Tulsa, OK).
Results
Identification of r1 Receptors in Human Cancer Cells
As shown in Figure 1, B–D, the four cancer cell lines under
study displayed different patterns of expression in the j1 re-
ceptor splice variants: U373-MG GBM cells did not express
any variant other than V1; C32 melanoma cells expressed V1,
V3 + V4, and, to a lesser extent, V2 + V5; and A549 NSCLC
and PC3 prostate cancer cells expressed all five variants.
In Vitro Characterization of 4-IBP–Mediated Effects
on the Overall Growth of Human Cancer Cell Lines
4-IBP was found to have weak antiproliferative effects
on human U373-MG GBM and C32 melanoma cells (Fig-
ure 2A). Indeed, even at 10 mM for 3 days, the highest 4-IBP
concentration tested, a maximum of only 10% growth inhibi-
tion was observed in these two cell lines. In contrast, 4-IBP
induced a concentration-dependent decrease in the growth
of human A549 NSCLC and PC3 prostate cancer cells (Fig-
ure 2A). Thus, A549 and PC3 cells, unlike C32 and U373-MG
cells, appear to be susceptible to 4-IBP–provoked cell death,
notably at concentrations of z 1 mM.
In Vitro Characterization of 4-IBP–Mediated Effects on
Cancer Cell Migration
Although 4-IBP was found not be antiproliferative at con-
centrations of up to 10 mM against C32 melanoma cells, the
compound was found to have significant antimigratory ef-
fects at concentrations between 1 and 100 nM in this cell line,
as evidenced by a significant decline in MRDO (Figure 2B).
Similar antimigratory features were observed with the three
other human cancer cell lines investigated: U373-MG GBM
(Figure 3E ), A549 NSCLC (data not shown), and PC3 (data
not shown).
Characterization of 4-IBP–Mediated Effects on Cell
Morphology and Actin Cytoskeleton Organization
Several steps in the cell migration process in extracellular
matrix environments are usually paralleled by marked modi-
fications in cell shape [21,22,37]. Figure 3A shows the four
quantitative features used to characterize cell morphology.
Degree of sphericity, elongation, and morphologic pattern are
three complementary variables that permit the evaluation of
the roundness of a cell (i.e., the farther is the value from 1, the
greater is the likelihood that a cell presents an elongated
morphology). In addition, a cell’s spread is evaluated by the
determination of its area. Although 4-IBP (1–100 nM) signifi-
cantly modified the migration levels of all four human cancer
cell lines investigated, in the present study, over the same
concentration range, it left the morphologic patterns of these
cells unchangedwhen compared to controls (data not shown).
Computer-assisted fluorescence microscopy was then
used to determine the effects of 1 and 10 nM 4-IBP (con-
centrations defined as antimigratory but noncytotoxic) on
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the organization of the actin cytoskeleton in U373-MG GBM
cells. Figure 3B illustrates the typical appearance of the actin
cytoskeleton in control U373-MG cells in which fibrillar (poly-
merized) actin appears as green fluorescence and globular
(nonpolymerized) actin appears as red fluorescence. Treat-
ment with 1 nM 4-IBP for 7 h increased the level of fibrillar
to the detriment of globular actin in human U373-MG cells
(Figure 3C). Furthermore, quantitative analysis revealed
that both 1 and 10 nM 4-IBP induced significant but tran-
sient increases in the levels of fibrillar actin in these cells
(Figure 3D). These effects could lead to a 4-IBP–induced
decrease in the levels of migration of these cells (Fig-
ure 3E ). As detailed below, part of 4-IBP–induced modifica-
tions to the organization of the actin cytoskeleton occurred
through compound-induced reduction in the expression of
Rho GDI.
Characterization of 4-IBP–Mediated Effects on
Intracellular Calcium Concentration in Human
U373-MG Glioblastoma Cells
It appears that 4-IBP may bind to various j1 receptor
variants [10]. In addition, a structurally diverse range of
compounds bind to j1 receptors, and a number of these
ligands interact with other receptor types [3]. One example of
poor specificity is the direct interaction between j receptor
ligands and N-methyl-D-aspartate (NMDA) receptors [3,25].
Activation of NMDA receptors is accompanied by a local
rise in [Ca2+]i, which is sufficient to trigger a slow and
sustained recruitment of actin in dendritic spines during
activity-dependent processes underlying neuronal plasticity
[38]. Dendritic spines, in fact, contain a specialized cyto-
skeleton consisting of dynamic actin filaments able to pro-
duce rapid changes in their motility and morphology [38].
Modifications to [Ca2+]i can thus seriously modify the orga-
nization of the actin cytoskeleton [39]. Although 4-IBP is a
selective j1 ligand [25], weak inhibition of cloned NMDA
receptor responses in Xenopus oocytes has nevertheless
been observed with this compound [3]. It was thus con-
sidered important to investigate whether the 4-IBP–induced
decrease in U373-MG GBM cell migration (Figure 3E ) and
associated changes in actin cytoskeleton organization (Fig-
ure 3, B–D) resulted from modifications in [Ca2+]i, as en-
countered in the activation of NMDA receptors [38]. The
data obtained at 10 nM strongly suggest that 4-IBP does
not modify U373-MG cell migration or the organization of
the actin cytoskeleton through modifications in [Ca2+]i in
Figure 3. Evaluation of 4-IBP– induced effects on U373-MG glioblastoma cells. (A) Illustration of the morphologic variables used to evaluate the roundness of a cell
(level of sphericity, elongation, and morphologic pattern) and its spread (area). (B and C) Illustration of actin cytoskeleton distribution in control U373-MG cells and
in those treated with 1 nM 4-IBP for 7 hours. Fibrillar actin and globular actin appear as green and red fluorescence, respectively. (D and E) Effects of two
concentrations of 4-IBP on fibrillar/globular actin ratios and cell motility levels computed over different time periods (as indicated on the x-axis). (F) 4-IBP (10 nM)
did not significantly increase [Ca2+]i in U373-MG GBM cells when compared to ionomycin.
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this cancer cell line (Figure 3F ). This, in turn, suggests that
4-IBP–mediated effects on U373-MG cell migration do not
occur through the compound’s activation of NMDA receptors.
Characterization of the Combined Influences of
4-IBP–Mediated Antimigratory Activity and Cytotoxic
Drug–Mediated Effects on the In Vitro Development
of Human U373-MG Glioblastoma Cell Populations
Migrating human cancer cells, in general [21], and human
glioblastoma cells, in particular [22], are protected against
apoptosis during migration. Several diverse compounds that
are able to decrease the levels of glioblastoma cell migration
also restore to these cells a certain level of sensitivity to
apoptosis [22,40]. This being the case, the ability of 4-IBP to
modify the in vitro sensitivity of human U373-MG apoptosis-
resistant glioblastoma cells [32] to the cytotoxic effects of
either a proapoptotic (lomustin) [41] or a proautophagic
(temozolomide) [28] drug was investigated.
Ten nanomolars of 4-IBP, when added to U373-MG cells
in the scratch wound assay 1 to 7 hours before the addition of
lomustin (1 and 10 mM) or temozolomide (1 and 10 mM),
resulted in significant (P < .01 to P < .001) sensitization of
these glioblastoma cells to the proapoptotic effects of 10 mM
lomustin (Figure 4A) or to the proautophagic effects of 1 and
10 mM temozolomide (Figure 4B). This sensitization was
essentially lost when 4-IBP was added 24 hours before the
addition of either cytotoxic agent.
4-IBP Does Not Induce Apoptosis in Human U373-MG
Glioblastoma Cells
The intracellular signaling pathways involved in the ac-
quisition of resistance to apoptosis (type I programmed cell
death) by migrating glioma cells concern PI3K, Akt, mTOR,
and NF-nB [22]. The PI3K and Akt signaling pathways are
interlinked in their regulation of cell survival and cell death in
human GBM cells [22]. The data in Figure 4, C and D,
Figure 4. (A and B) Therapeutic combination of 4-IBP and cytotoxic agents [(A) lomustin and (B) temozolomide] in a scratch wound assay in which colonization by
human U373-MG GBM cells of an artificially inflicted wound in a subconfluent cell population was followed over time. (A) and (B) illustrate delay in the wound
healing process when U373-MG cells were pretreated with 4-IBP [10 nM; duration exposure varied from 0 (no 4-IBP treatment) to 24 hours on the x-axis] before the
cytotoxic insult with lomustin or temozolomide, respectively, used at 1 M (open dots) or 10 M (open squares) over 16 hours. Controls were U373-MG cells
cultured in the absence of 4-IBP, lomustin, or temozolomide, and were arbitrarily normalized to 100% wound colonization after 24 hours of culture (open triangles in
A and B). An additional control was performed for each treatment [i.e., lomustin or temozolomide added alone at 1 M (black lozenge) or at 10 M (white lozenge)
for 16 hours to the cells, and 4-IBP at 10 nM for 7 and 24 hours of exposure (white triangles)]. (C and D) Evaluation of the levels of expression of total (black bars)
and phosphorylated (open bars) p85-PI3K (C) and Akt (D) in U373-MG GBM cells left untreated (Ct) or treated with 10 nM 4-IBP for the periods indicated. The data
are expressed as mean ± SEM. Assays were validated using serum-starved U373-MG treated with epidermal growth factor (200 ng/ml) for 10 minutes (C+). (E)
Western blot analyses of PARP cleavage and p53 expression in U373-MG cells left untreated (0) or treated with 10 nM 4-IBP for between 48 and 96 hours.
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indicate that 4-IBP at 10 nM did not modify the pattern of
expression of total and phospho p85-PI3K and Akt in U373-
MG GMB cells. It is thus unlikely that 4-IBP–mediated
sensitization of these cells to the proapoptotic effects of
lomustin could relate to compound-mediated modifications
to the PI3K/Akt signaling pathway.
The data in Figure 4Ea indicate that treatment of U373-MG
cells with 10 nM 4-IBP for 48 to 96 hours induced weak, if
any, apoptosis-related PARP cleavage. Flow cytometry analy-
ses of TUNEL staining confirmed the absence of 4-IBP–
induced apoptotic features at 10 and 100 nM in U373-MG
cells (data not shown). Figure 4Eb shows that the levels of
expression of p53 protein in untreated U373-MG cells were
high and that 10 nM 4-IBP did not modify this expression.
4-IBP Does Not Induce Autophagy in Human U373-MG
Glioblastoma Cells
As shown by the use of acridine orange staining (Fig-
ure 5A), the treatment of U373-MG cells for 72 hours with
increasing concentrations of 4-IBP did not induce any sig-
nificant (P > .05) increase in the percentages of acidic com-
partments. Such acidic vesicular organelles may relate to
autophagic vacuoles in the cells [28,42]. The data in Figure 5,
B and C, confirm those illustrated in Figure 5A. Indeed, even
at high concentrations (10 mM), 4-IBP did not increase
markedly the levels of expression of LC3 and Beclin-1, two
specific markers of autophagy [28,42]. Modifications to the
percentage of acridine orange staining in tumor cells may
also relate to lysosomal membrane permeabilization (LMP),
an Hsp70-dependent process [43] that may be indicative of
the leakage of acridine orange from the acidic compartment
to the cytosol [43]. The data in Figure 5D show that 4-IBP (up
to 10 mM) did not markedly modify the levels of expression
of Hsp70.
4-IBP Does Not Interfere with Responses to
Endoplasmic Reticulum Stress (ERS)
ERS arises from the fact that cancer cells in poorly
vascularized solid tumors (including GBMs) are constantly
or intermittently exposed to nutrient and glucose deprivation,
hypoxia, redox and glycosylation reactions, and disturbances
in calcium mobilization [44,45]. Under such conditions, eu-
karyotic cells normally respond through at least three different
mechanisms, namely, transcriptional induction, translational
attenuation, and degradation (ER-associated degradation)
[44–46]. Transcriptional induction derives from the activation
of an intracellular signaling pathway from the ER to the nu-
cleus, which is known as unfolded protein response (UPR)
[44,46]. Excessive or long-term stress in the ER results in
apoptotic cell death involving nuclear fragmentation, chro-
matin condensation, and cell body shrinkage [44]. A lower
level of susceptibility to cell death on the activation of the
UPRmay contribute to tumor progression and drug resistance
of solid tumors [44]. Thus, the inhibition of the UPR might
Figure 5. (A) The detection and quantification of acidic vesicular organelles by acridine orange staining using flow cytometry in human U373-MG GBM cells treated
for 72 hours with increasing concentrations of 4-IBP. In acridine orange–stained cells, the cytoplasm and nucleus fluoresce green (y-axis), whereas acidic
compartments fluoresce red (x-axis). The intensity of the red fluorescence is proportional to the degree of acidity and to the volume of acidic vesicular organelles,
including autophagic vacuoles. The values in (A) refer to the percentages of cells with a significant proportion of acidic vesicular organelles. (B–F) Western blot
analyses of Beclin-1 (B); microtubule-associated protein 1 LC3 (an autophagosomal orthologue of yeast Atg8/Aup7) type I (LC3-I) and type II (LC3-II) (C); Hsp70
(D); GRP78 (E); and ORP150 (F) in human U373-MG glioblastoma cells treated with increasing concentrations of 4-IBP for 72 hours.
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improve the effectiveness of chemotherapy [44]. ER chaper-
ones, such as GRP78 and Gadd153, play a number of critical
roles in cell survival and cell death as part of the UPR [44].
GRP78 is also involved in cancer cell resistance to cyto-
toxic drugs [47]. ORP150 is also a component of the ERS
response to hypoxia, potentially facilitating protein processing
[46]. ORP150 was first identified and cloned from cultured
astrocytes based on their ability to withstand and even pro-
duce neurotrophic factors in response to severe hypoxia [46].
The expression of ORP150 in cultured human cells is essen-
tial for their survival under prolonged hypoxia [46]. Because
GRP78 and ORP150 are major players in the ERS responses
of cancer cells to cytotoxic agents [44–47], an investigation
was undertaken to ascertain whether 4-IBP could modify
their levels of expression in human U373-MG GBM cells.
The data in Figure 5E show that even at high concentrations
(10 mM), 4-IBP did not modify the levels of expression of
GRP78. The same observation was made in the case of
Gadd153 (data not shown). In the same way, the data in Fig-
ure 5F show that 4-IBP did not modify the levels of expres-
sion of ORP150 in human GBM cells. Taken together, these
data suggest that it is unlikely that the 4-IBP–mediated sen-
sitization of U373-MG GBM cells to the proapoptotic effects
of lomustin (Figure 4A) or proautophagic effects of temozolo-
mide (Figure 4B) relates to induced modification to ERS.
4-IBP Markedly Reduces the Levels of Expression
of Rho GDI and GCS in U373-MG GBM Cells
The failure to evidence any 4-IBP–mediated influence on
proapoptotic (Figure 4, C–E ), proautophagic (Figure 5, A–
C), pro-LMP (Figure 5, A and D), or pro-ERS responses
(Figure 5, E and F ) prompted the treatment of U373-MG
GBM cells with 10 nM 4-IBP for 12 hours, followed by a
genomewide microarray analysis of treated cells, to try and
elucidate how the compound sensitizes these glioblastoma
cells to the cytotoxic insults of lomustin and temozolomide
(Figure 4, A and B). Genomic analysis revealed that the two
genes whose levels were most heavily modified in these
4-IBP–treated cells (30–50% decrease in their expression
compared to controls) wereRho GDI andGCS.Rho GDI and
GCS are genes known to be involved in drug resistance
[48–50]. Immunofluorescence analyses confirmed these
data at the proteomic level. Figure 6A shows a concentrated
and perinuclear site for Rho GDI in U373-MG GBM un-
treated cells. This site became diffuse when these cells were
treated for 72 hours with 1 nM 4-IBP (Figure 6B), and Rho
GDI expression was almost completely abolished when the
cells were treated for 72 hours with 10 nM 4-IBP (Figure 6C).
The treatment of U373-MG GBM cells with 1 and 10 nM
4-IBP for 72 hours also produced similar effects in the case
of GCS expression (Figure 6, E and F ), which again was al-
most completely abolished at the higher 4-IBP concentration
compared to controls (Figure 6D).
In Vivo Characterization of 4-IBP–Induced Effects on the
Survival of Immunodeficient Mice Bearing Orthotopic
U373-MG Glioblastoma or A549 NSCLC Xenografts
4-IBP significantly (P = .03) increased the survival of
orthotopic U373-MG GBM xenograft-bearing mice and also
significantly (P = .02) increased the therapeutic benefit of
Figure 6. Immunofluorescence analyses in the investigation of the expression of Rho GDI (A–C) and GCS (D–F) in U373-MG GBM cells left untreated (A and D)
or treated for 72 hours with 1 nM 4-IBP (B and E) and 10 nM 4-IBP (C and F). The levels of expression of Rho GDI and GCS are shown as red fluorescence (right
panels), with bright-field microscope analysis (left panels) as morphologic control.
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temozolomide (Figure 7A). In the same manner, 4-IBP sig-
nificantly (P = .02) increased the therapeutic benefits con-
tributed by IRI in the A549 NSCLC orthotopic xenograft
model, whereas it was unable per se to augment significantly
the survival of A549 NSCLC-bearing mice (Figure 7B).
Although IRI is not the first choice for lung cancer, we
nevertheless chose it because it is the only cytotoxic drug
that displayed previously therapeutic benefits in the A549
NSCLC orthotopic model [36].
Discussion
Although there is considerable evidence for the involvement
of j receptors in cancer cell biology, the mechanism(s)
through which these implications occur has not fully been
identified [4]. In fact, j1 receptors and/or j1 drugs could
produce their anticancer effects by modulating ion channels
such as high-voltage–activated Ca2+ channels, including N,
L, P/Q, and R types, and voltage-gated K+ channels [4]. In
their recent review of the potential involvement of j receptors
in cancer biology, Aydar et al. [4] report that, to date, studies
on the j1 receptor modulation of K+ channels have deduced
that the signal transduction mechanism of j1 receptors: 1) is
membrane-bound; 2) is independent of G-protein coupling
and protein phosphorylation; 3) can be reconstituted in a
heterogenous system; and 4) does not require cytoplasmic
factors but 5) does require the j1 receptor and the K+
channel to be in close proximity, in all probability to form a
stable macromolecular complex.
The data from the present study have demonstrated
through the use of a selective j1 receptor agonist 4-IBP
the involvement of j1 receptors in cancer cell migration and
the sensitization of cancer cells to cytotoxic insults from
proapoptotic and proautophagic drugs, at least in human
U373-MG GBM cells. These two processes may well be
connected, as explained below.
It has been postulated that j1 receptors may play a role in
the organization of the actin cytoskeleton by controlling the
functioning of cytoskeletal proteins such as ankyrins, which
are cytoskeletal adaptor proteins that control Ca2+ efflux at
IP3R-3 on the endoplasmic reticulum [51]. Whereas we
observed that 4-IBP modifies the organization of the actin
cytoskeleton in human U373-MG glioblastoma cells, no cor-
responding changes to [Ca2+]i were observed in these cells.
Cancer cell migration, a hallmark of glioma cell biology
[52,53], is the biologic process that ultimately leads to the
development of metastases (excepted in gliomas), and about
90% of cancer patients die from their metastases. Migrating
cancer cells are resistant to apoptosis [21,22], and a majority
of anticancer drugs used to treat cancer patients are pro-
apoptotic agents and thus are weakly effective against
metastases [21]. The acquisition of resistance to apoptosis
is essential for cancers to develop and progress, and is a
major reason behind treatment failures [19]. In fact, cancer
cells undergo clonal unrestrained proliferation, transgress
normal tissue boundaries, and migrate to distant parts [19].
To disregard microenvironmental constraints in this way,
tumor cells must acquire resistance to apoptosis [19,21,22]
or they will die when deprived of the support of familiar
neighbors [19,21,22]. Spruce et al. [19] have shown that
small molecule antagonists of the j1 receptor inhibit tumor
cell survival and induce caspase-dependent apoptosis. Al-
though several normal cell types, such as fibroblasts, epithe-
lial cells, and even j receptor–rich neurons, are resistant to
the apoptotic effects of antagonists, cells that can promote
autocrine survival, such as lens epithelial and microvascular
endothelial cells, are as susceptible as tumor cells [19]. Cell
susceptibility appears to correlate with differences in j1
receptor coupling rather than with levels of expression [19].
Only in the case of susceptible cells do j1 antagonists evoke
a rapid rise in cytosolic calcium that is inhibited by j1 ago-
nists [19]. The present study has revealed that U373-MG
glioblastoma cells, which contain only variant 1 of the j1
receptor (Figure 1), are not susceptible to 4-IBP, which is an
agonist, not an antagonist, of the j1 receptor. In addition, it
must be emphasized that all in vitro data reported by Spruce
et al. [19] with respect to the apoptotic features induced by j1
receptor antagonists were observed with such antagonists
Figure 7. (A) The survival of mice orthotopically (brain) grafted with human
U373-MG GBM cells after treatment with 4-IBP alone (red line) or combined
with temozolomide (purple line), compared to temozolomide alone (green
line) and controls (blue line). (B) The survival of mice orthotopically (lung)
grafted with human A549 NSCLC cells after treatment with 4-IBP alone (red
line) or combined with IRI (purple line), compared to IRI alone (green line) and
controls (blue line).
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only when used in themicromolar range, whereas our data on
the effects of the j1 receptor agonist 4-IBP on cancer cell
migration are based on nanomolar concentrations.
Whereas U373-MG GBM cells are resistant to apop-
tosis [32] (manuscript in preparation), the fact that low
concentrations of 4-IBP modulate both migration and sensi-
tivity to proapoptotic and proautophagic cytotoxic insults in
these cells could be at least partly explained by the fact that
these low concentrations also markedly decrease the levels
of expression of Rho GDI in U373-MG GBM cells (Figure 6).
In fact, Rho GDI plays an essential role in controlling a
variety of cellular functions through interactions with Rho
family GTPases, including Rac1, Cdc42, and RhoA [48].
Zhang et al. [48] have shown that the Rho GDI widely
expressed in hematopoietic cells (D4-GDI) is also expressed
in a panel of breast cancer cell lines, but not in benign-
derived mammary epithelial cells, and that the knockdown of
this protein’s expression blocks cell motility and invasion.
Rho GDI is also frequently overexpressed in different human
tumors and chemoresistant cancer cell lines, further sug-
gesting that it might play a role in the development of drug
resistance in cancer cells [48,54]. It has also been proven
that Rho GDI expression is a predictive marker of paclitaxel
resistance not only in paclitaxel-resistant ovarian cancer cell
lines but also in clinical samples [54]. Zhang et al. [48]
observed that the overexpression of Rho GDI increases
the resistance of cancer cells to the induction of apoptosis
by etoposide and doxorubicin. Conversely, the silencing of
Rho GDI expression by DNA vector–mediated RNA inter-
ference (small interfering RNA) sensitizes tumor cells to
drug-induced apoptosis [48].
The overexpression of GCS, a pivotal enzyme in glycolipid
biosynthesis, also contributes to cancer cell resistance to
chemotherapy [49,50]. The present study revealed that
10 nM 4-IBP noticeably reduced the levels of expression of
GCS in human U373-MGGBM cells (Figure 6). Using a series
of drug-resistant human epidermoid carcinoma, breast, leu-
kemia, melanoma, and colon cancer cell lines developed
through selection pressure cloning with various anticancer
drugs (adriamycin, vincristine, etoposide, and doxorubicin),
Gouaze´ et al. [49,50] observed that increases in drug resis-
tance are accompanied by increases in the expression and
activity of GCS. These authors show that limiting GCS ac-
tivity by antisense transfection or chemical inhibition restores
cell chemosensitivity and downregulates the expression of
MDR1, a phenomenon that may drive chemosensitization
associated with blocking ceramide metabolism [49].
Given its ability to sensitize cancer cells to cytotoxic agents
in vitro, 4-IBP was found to significantly increase the survival
of orthotopic U373-MG GBM xenograft-bearing mice and the
therapeutic benefit of proautophagic temozolomide. 4-IBP
also significantly increased the therapeutic benefits con-
tributed by proapoptotic IRI in the A549 NSCLC orthotopic
xenograft model, whereas it was unable per se to augment
significantly the survival of A549 NSCLC-bearing mice.
In conclusion, activating the j1 receptor with noncytotoxic
doses of the j1 receptor agonist 4-IBP decreases the migra-
tion levels of various types of cancer cells, including C32
melanoma, U373-MG glioblastoma, A549 NSCLC, and PC3
prostate cancer cells. This activation in U373-MG glioblas-
toma cells displaying the j1 receptor V1 transcript variant
only leads to their sensitization to proapoptotic or proauto-
phagic cytotoxic insults, a process in which Rho GDI and
GCS seem to be involved.
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